DPP-4 inhibition and blood pressure lowering in perspective

Journal of Hypertension

Volumn 34, Issue 2, 2016, Pages 184-187

  Nilsson, Peter M ^a   Diez, Javier ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b Centre for Applied Medical Research   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALOGLIPTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD CLOT LYSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMODYNAMIC MONITORING; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTERVENTION STUDY; KIDNEY DISEASE; LONG TERM CARE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SODIUM URINE LEVEL; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84957434587     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000814     Document Type: Review

References (24)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: A patientcentered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55:1577-1596.
2. deMelloAH, Prá M, Cardoso LC, deBona Schraiber R, RezinGT. Incretinbased therapies for obesity treatment. Metabolism 2015; 64:967-981.
3. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al., SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317-1326.
4. WhiteWB, Cannon CP, Heller SR, Nissen SE, BergenstalRM, Bakris GL, et al., EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369:1327-1335.
5. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al., TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373:232-242.
6. Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al., ELIXA Investigators. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J 2015; 169:631-638.
7. Balfour PC Jr, Rodriguez CJ, Ferdinand KC. Blood pressure and cardiovascular effects of new and emerging antidiabetic agents. Curr Hypertens Rep 2014; 16:455.
8. Wang T, Gou Z, Wang F, Ma M, Zhai SD. Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PLoS One 2014; 9:e103798.
9. Lovshin JA, Zinman B. Blood pressure-lowering effects of incretinbased diabetes therapies. Can J Diabetes 2014; 38:364-371.
10. Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis. J Hypertens 2016; 34:167-175.
11. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48:592-598.
12. Sufiun A, Rafiq K, Fujisawa Y, Rahman A, Mori H, Nakano D, et al. Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hypertens Res 2015; 38:237-243.
13. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; [Epub ahead of print].
14. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014; 130:1579-1588.
15. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet 2015; 385:2067-2076.
16. McMurray J. The vildagliptin in ventricular dysfuntion diabetes trial (VIVIDD). Eur Heart Failure Cong, Lisbon, Portugal, 28 May. 2013.
17. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34:3035-3087.
18. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: A systematic review and metaanalysis. JAMA 2015; 313:603-615.
19. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): A randomised controlled trial. Lancet 2005; 366:1279-1289.
20. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and antiatherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs 2009; 18:1495-1503.
21. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
22. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al., ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213.
23. Berglund LM, Lyssenko V, Ladenvall C, Kotova O, Edsfeldt A, Pilgaard K, et al. Glucose-dependent insulinotropic polypeptide (GIP) stimulates osteopontin expression in the vasculature via endothelin-1 and CREB. Diabetes 2015; [Epub ahead of print].
24. Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA1). Diab Vasc Dis Res 2015; 12:164-174.